Rhythm Pharmaceuticals (RYTM) is down about 3% in Friday trading, extending a volatile stretch following its recent U.S. label expansion for IMCIVREE (setmelanotide) in acquired hypothalamic obesity. The move appears driven by a mix of post-catalyst repositioning after the FDA decision and ongoing investor sensitivity to any perceived capital-raising or dilution risk typical for commercial-stage biotechs scaling a launch.

On March 19, 2026, the FDA approved an expanded indication for IMCIVREE to treat acquired hypothalamic obesity in adults and pediatric patients aged 4 and older, making it the first FDA-approved therapy for this condition. The approval was supported by the Phase 3 TRANSCEND trial (N=142), which reported a placebo-adjusted BMI reduction of 18.4% at 52 weeks, and the company said IMCIVREE would be available immediately in the U.S. through its Rhythm InTune support program.

After a binary regulatory event is resolved, biotech stocks often trade on execution risk: payer coverage, diagnosis/referral funnel build, and the pace at which eligible patients start therapy. Rhythm also faced a financing narrative earlier in 2026, including an at-the-market equity facility and a marketed offering announcement in March, which can keep a “dilution overhang” in the stock even after a major FDA win.

Investors will be looking for early evidence of launch traction in acquired hypothalamic obesity, including reimbursement progress, patient starts, and any updated commercial guidance tied to the new indication. Additional corporate updates, including governance changes disclosed in early April, are likely secondary to near-term questions about how quickly the newly approved market converts into measurable revenue growth.